论文部分内容阅读
目的研究BTB/P0Z蛋白家族成员Kaiso在乳腺癌组织中的表达及其与乳腺癌临床病理学参数的关系。方法应用免疫组织化学法研究120例不同临床分期乳腺癌组织及39例乳腺增生组织中Kaiso的表达情况与亚细胞定位,并对其与乳腺癌临床病理参数进行相关性分析。结果免疫组织化学染色表明在120例乳腺癌组织中Kaiso呈明显的核表达,核阳性率为65.00%(78/120),而在39例对照组乳腺增生组织中呈零或极微弱的表达。Kaiso蛋白核表达与乳腺癌组织TNM分期(P=0.000)和淋巴结转移(P=0.001)呈正相关;而与乳腺癌患者的性别、年龄以及乳腺癌组织分化程度均无明显相关性(P>0.05)。结论 Kaiso在乳腺癌中主要为核表达,且Kaiso的表达与乳腺癌的恶性表型及转移呈正相关,提示Kaiso可能成为乳腺癌新的肿瘤标志物和治疗靶点。
Objective To study the expression of Kaiso in BTB / P0Z protein family in breast cancer and its relationship with clinicopathological parameters of breast cancer. Methods Immunohistochemical method was used to study the expression and subcellular localization of Kaiso in 120 cases of breast cancer and 39 cases of breast hyperplasia. The correlation between Kaiso and breast cancer clinicopathological parameters was analyzed. Results The immunohistochemical staining showed that the nuclear positive expression rate of Kaiso was 65.00% (78/120) in 120 cases of breast cancer tissues, while it was zero or very weak in 39 cases of breast hyperplasia tissues. There was a positive correlation between Kaiso protein nuclear expression and TNM staging (P = 0.000) and lymph node metastasis (P = 0.001) in breast cancer tissues, but no significant correlation with sex, age and breast cancer differentiation (P> 0.05 ). Conclusions Kaiso is mainly expressed in breast cancer, and the expression of Kaiso is positively correlated with the malignant phenotype and metastasis of breast cancer, suggesting that Kaiso might be a new tumor marker and therapeutic target for breast cancer.